Study of ustekinumab or apremilast for Behçet's disease symptoms
Part of Eyes & vision, Genetic & congenital, Heart & circulation, Mouth & dental, Skin clinical trials.
This study tests if ustekinumab or apremilast can help control Behçet's disease symptoms like mouth and genital ulcers, skin sores, and joint pain. It may be an option if standard treatments haven't worked well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have been diagnosed with Behçet's disease
- You have active mouth or genital ulcers, skin sores, or joint pain that keep coming back
- You have had at least 2 mouth ulcers in the past month and 3 or more episodes of mouth ulcers in the last year
- You have not tried ustekinumab before or it didn't work for you
- You do not have severe infections, cancer, or major kidney/liver problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called corticotropin (a hormone that may help control inflammation) to see if it can reduce symptoms of Behçet's disease, especially painful mouth ulcers. If you have active ulcers, this treatment might help you get relief.
This trial studies whether apremilast can help reduce mouth ulcers in children who have Behçet’s disease or juvenile psoriatic arthritis. You may be considered if your child finished a main study and is under 18, and can safely continue treatment.
This study tests apremilast to help reduce active, recurring mouth (oral) ulcers in children with Behçet’s disease. It may help if your child has had repeated mouth ulcers despite at least one non-biologic treatment.
This trial tests a new medicine, HSK44459, to see if it can reduce mouth ulcers in people with Behçet's disease. If you have frequent mouth sores from Behçet's, this treatment might help.
This Phase 2 trial tests tocilizumab and tofacitinib to see if they can better control vascular (blood-vessel) Behçet’s syndrome. It may help by lowering inflammation and reducing complications from aneurysms in the aorta or peripheral arteries.
This study compares two biologic medicines, adalimumab and tocilizumab, to see which works better for severe eye inflammation (uveitis) caused by Behçet's disease. Both are given as injections, and the goal is to improve vision and reduce eye damage.
Hear when a new Behçet's Syndrome (BS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.